The Cash Machine Behind Novonesis's India Bet

Novonesis is spending €600 million to build a next-generation enzyme production plant in Patalganga, India — one it expects to come online around 2030. The announcement reads like a growth story: expand capacity, chase demand in emerging markets, build for a decade out. That part is real. But the more immediately relevant story has nothing to do with a factory four years away. It's that this business is already printing free cash flow at a rate its own management seems to have only recently started believing in.

In 2025, Novonesis converted 19% of sales into free cash flow before acquisitions — €770 million. That's not a startup running toward profitability. That's a mature, dominant business collecting cash from the kinds of industrial enzymes that end up in your laundry detergent, your bread, your biofuel, and your animal feed. With nearly 50% market share in industrial enzymes and a similar position in microbial cultures, this isn't a company that needs to prove the market exists. It's a company that decides how fast the market grows.

Then in August 2026, the company raised its full-year organic sales guidance to 7–8% from 5–7%, positioned adjusted EBITDA margins at the higher end of 37–38%, and announced its first-ever share buyback: €1 billion, to be deployed through 2029. The stock jumped 8.5% on the day. The market heard what management was really saying: we don't need to reinvest all this cash just to keep the lights on. There's room to give some back.

That shift from full-reinvestment mode to cash-generation-plus-buyback mode is the inflection. Not the India plant. The India plant is what a confident company does when it can afford to think about 2030.

How much cash are we talking about?

The H1 2026 numbers tell the story. Sales for the six months reached €2.24 billion, up 8% organically from a year ago. Adjusted gross margin improved 100 basis points to 59.7%. Adjusted EBITDA margin reached 37.7%. Free cash flow before acquisitions was €307.6 million — 14% of sales in the first half, against a backdrop of €216 million in capital expenditures.

That 14% first-half FCF conversion looks lower than the 19% full-year rate from 2025. The gap isn't a business deterioration; it's a rhythm issue. Capital spending in the first half is typically front-loaded around large equipment orders, and the company is actively building out capacity across several sites. The €600 million India project will add to capex over the coming years, but it's one facility spread across multiple years within a business that generates roughly €4 billion in annual revenue. On that scale, a single new plant is an investment, not a cash-flow sink.

More telling is what's happened to earnings. Adjusted EPS for H1 2026 was €1.09, up 9% year over year. Annualized, that's roughly €2.18 per share. The stock is trading around DKK 455, which at the pegged euro exchange rate of roughly 7.475 DKK per euro works out to about €60.8 per share. That implies a forward P/E in the low-to-mid 20s — consistent with the forward multiples reported around 26x on other data feeds that use slightly different earnings estimates.

Twenty-six times forward earnings on a company growing revenue at 7–8% with EBITDA margins near 38% is not cheap. It's the price a dominant market leader commands when cash flow conversion is reliable and the balance sheet is clean. Net interest-bearing debt to EBITDA stood at 1.8x in H1 2026, down from 1.9x at year-end 2025. Management is targeting roughly 1.5x by 2030.

The expectations reset that's already working

Here's where the setup matters. Novonesis is the merged entity of Novozymes and Chr. Hansen, combined in January 2024. Mergers are supposed to be the messy middle: integration costs, culture clashes, synergy disappointments. The stock fell from its post-merger highs to a 52-week low of DKK 337 before recovering to its current level near DKK 455. That's the tape pain.

The business pain was much milder. The merger produced the synergies management promised — about 1 percentage point of organic sales growth in both H1 2025 and H1 2026, on top of price and volume gains. Gross margin expanded 240 basis points in 2025 and another 100 basis points in H1 2026. Operating costs rose slightly to 29.1% of sales in H1 2026, reflecting commercial hiring and the recent Feed Enzymes Alliance acquisition, but that's the cost of growing a business, not the symptom of one that's losing focus.

The market has already moved on. The stock is sitting at 99% of its 52-week high. A €1 billion buyback announced in August followed an 8.5% single-day rally. The aggregate signal here isn't skepticism — it's conviction. The expectations reset that usually creates the best entry point has already happened. The bar is no longer low; it's been lifted.

Where the valuation gets interesting

This is the question a buyer at these levels needs to answer: is the improvement durable enough to support the multiple, or is the market already pricing a best-case scenario?

On the durable side, the business model is structurally unattractive to competitors and structurally attractive to owners. Enzymes are biological catalysts — proprietary proteins developed through years of strain engineering and fermentation expertise. Novonesis holds an unmatched library of strains and enzyme classes, protected by patents and a decade-deep R&D pipeline. Thirty-three new products launched in 2025. Innovations from the last five years already account for 25% of sales. That's a product engine, not a cost center.

The margin quality is also hard to fake. A 38% EBITDA margin on a 60% gross margin means the operating expense stack is about 22% of revenue — an unusually thin layer for a global, multi-site manufacturer. That's the kind of profitability that survives currency headwinds, competitive pricing pressure, and cyclical soft patches. In H1 2026, the EBITDA margin expanded 30 basis points year over year despite estimated 50 basis points of currency headwinds.

On the other side, a forward P/E near 26x leaves little room for execution misses. The company exited certain countries in both 2025 and H1 2026 — a cumulative 1.5 percentage-point drag on organic growth in the first half alone. Emerging market growth is the long-term tailwind, but it's also where political, regulatory, and currency risks cluster. The cautious North American dietary supplements market already showed up as a drag on the Human Health sub-segment, which grew just 4% in H1 2026. And the €600 million India plant, while strategically sound, is a commitment that will show up in capex reports for years before it shows up in revenue.

There's also the question of whether 7–8% organic growth at 38% margins is a trend or a peak. The company operates in mature categories — household care, food processing, animal feed, biofuels. These aren't hypergrowth markets. The growth Novonesis delivers comes from pricing power, share gains, and product innovation within a slowly expanding addressable market. That's high-quality growth, but it's not the kind that justifies an unlimited premium.

The break condition

For this thesis to work, the cash flow conversion needs to hold or improve. Specifically, full-year 2026 free cash flow should match or exceed the €770 million it generated in 2025, even with the India investment accelerating and the €1 billion buyback beginning to drawdown. If FCF conversion drops below 15% of sales for a full year while capex rises, the forward multiple loses its anchor. That's the condition that would break the rerating story.

The €1 billion buyback adds a second layer of proof. Management can't buy back shares it doesn't expect to generate the cash for. The program runs through 2029, which means roughly €330 million per year — about 8% of annual sales. If the company commits to that pace and delivers, it's a four-year signal that free cash flow is structural, not cyclical. If it slows or pauses, that tells you the cash flow bridge was thinner than advertised.

What you're buying

You're not buying a turnaround. You're not buying a beaten-down name that's still persuading the market it deserves mercy. You're buying a dominant, cash-generative business that has already earned its premium and is now asking whether the premium can grow further. The India expansion is the confidence signal — a €600 million bet placed with surplus cash on a demand trajectory four years out. The buyback is the proof — €1 billion returned because the cash flow is real and the management team has decided the shares are worth the ask.

The question at these levels is narrower: can a company growing at 7–8% with 38% EBITDA margins and 19% FCF conversion justify 26x earnings, or is the upside already reflected in the price? The cash flow says it can — as long as it keeps showing up. The valuation says the market has already decided it will.